Michael Kelly

Mr. Michael A. Kelly is an Independent Director at Prime Medicine, Inc., an Independent Director at DMC Global, Inc., a Lead Independent Director at NeoGenomics, Inc. and a President at Sentry Hill Partners LLC.
He is on the Board of Directors at Chroma Medicine, Inc., Prime Medicine, Inc., DMC Global, Inc., NeoGenomics, Inc. and NeoGenomics Laboratories, Inc. Mr. Kelly was previously employed as an Independent Director by Amicus Therapeutics, Inc., an Independent Director by Aprea Therapeutics, Inc., an Independent Director by HOOKIPA Pharma, Inc., a Senior Vice President-Global Business Services by Amgen, Inc., a Chief Financial Officer by Tanox, Inc., a Vice President-Finance & Controller by Biogen Idec, Inc., a Chief Financial Officer & Vice President-Finance by Nutrasweet Kelco Co. Ltd., a Chief Financial Officer & Vice President by The NutraSweet Co., a Principal by Onyx Capital Management LLC, and a Chief Financial Officer by Monsanto Life Sciences Co. He also served on the board at Hookipa Biotech AG and Direct Relief.
He received his undergraduate degree from Florida A&M University.